Loxl3 can promote tumor cell invasion in GBM (Laurentino et al., 2021), and Loxl4 is recognized as a stemness-related prognostic biomarker in glioma (Lvu et al., 2020). This evidence concerns the gene LOXL3 and central nervous system cancer.